Monday, July 13, 2015

AnaptysBio Names CFO

San Diego-based AnaptysBio, which is developing antibodies to treat inflammation and other issues, has named Robert E. Hoffman as its new Chief Financial Officer. Hoffman was most recently CFO of Arena Pharmaceuticals, and also served at Polaris Group, also as CFO. He sits on the boards of CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Kura Oncology. AnaptysBio currently has a number of programsnning with Novartis, Gilead, Celgene, Momenta and TESARO.